Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Maximum power |
During the incremental test until exhaustion, the power generated was measured maximum power (W) |
Throughout study completion, an average of 8 weeks |
|
Primary |
Power generated at FatMax |
During the incremental test until exhaustion, the power generated was measured in FatMax (W) |
Throughout study completion, an average of 8 weeks |
|
Primary |
Power generated at ventilatory threshold 1 (VT1) |
During the incremental test until exhaustion, the power generated was measured in VT1 (W) |
Throughout study completion, an average of 8 weeks |
|
Primary |
Power generated at ventilatory threshold 2 (VT2) |
During the incremental test until exhaustion, the power generated was measured in VT2 (W) |
Throughout study completion, an average of 8 weeks |
|
Secondary |
Fat mass |
Fat mass (g) was measured by densitometry and anthropometry. |
Throughout study completion, an average of 8 weeks |
|
Secondary |
Sum of 8 skinfolds |
By means of anthropometry, the sum of 8 skinfolds (mm) was calculated. |
Throughout study completion, an average of 8 weeks |
|
Secondary |
Muscle mass |
Muscle mass (g) was measured by densitometry and anthropometry |
Throughout study completion, an average of 8 weeks |
|
Secondary |
Resting metabolic rate |
Resting metabolic rate was measured by indirect calorimetry. |
Throughout study completion, an average of 8 weeks |
|
Secondary |
Superoxide dismutase (antioxidant marker) |
During the rectangular test, superoxide dismutase (U/g Hb) was measured in venous blood. |
Superoxide dismutase was measured in pre, after the maximum power phase of the rectangular test and after the recovery phase in pre and post intervention (8 weeks) in both groups. |
|
Secondary |
Catalase (antioxidant marker) |
During the rectangular test, catalase (U/g Hb) was measured in venous blood. |
Catalase was measured in pre, after the maximum power phase of the rectangular test and after the recovery phase in pre and post intervention (8 weeks) in both groups. |
|
Secondary |
Reduced glutathione (antioxidant marker) |
During the rectangular test, reduced glutathione (GSH) (nmol/mg protein) was measured in venous blood. |
Reduced glutathione was measured in pre, after the maximum power phase of the rectangular test and after the recovery phase in pre and post intervention (8 weeks) in both groups. |
|
Secondary |
Oxidized glutathione (antioxidant marker) |
During the rectangular test, oxidized glutathione (GSSG) (nmol/mg protein) was measured in venous blood. |
Oxidized glutathione was measured in pre, after the maximum power phase of the rectangular test and after the recovery phase in pre and post intervention (8 weeks) in both groups. |
|
Secondary |
GSSG/GSH ratio (antioxidant marker) |
During the rectangular test, GSSG/GSH ratio (%) was measured in venous blood. |
GSSG/GSH ratio was measured in pre, after the maximum power phase of the rectangular test and after the recovery phase in pre and post intervention (8 weeks) in both groups. |
|
Secondary |
Hemoxigenase 1 (antioxidant marker) |
During the rectangular test, hemoxigenase 1 (ng/mL) was measured in venous blood. |
Hemoxigenase 1 was measured in pre, after the maximum power phase of the rectangular test and after the recovery phase in pre and post intervention (8 weeks) in both groups. |
|
Secondary |
Thiobarbituric acid reactive substances (oxidant marker) |
During the rectangular test, thiobarbituric acid reactive substances (TBARS) (mcm/L) ( are formed as a byproduct of lipid peroxidation) was measured to determine the oxidative state in venous blood. |
Thiobarbituric acid reactive substances was measured in pre, after the maximum power phase of the rectangular test and after the recovery phase in pre and post intervention (8 weeks) in both groups. |
|
Secondary |
Interleukin 6 (inflammatory marker) |
During the rectangular test, interleukin 6 (pg/ml) was measured in venous blood. |
Interleukin 6 was measured in pre, after the maximum power phase of the rectangular test and after the recovery phase in pre and post intervention (8 weeks) in both groups. |
|
Secondary |
Tumor necrosis factor (inflammatory marker) |
During the rectangular test, tumor necrosis (pg/ml) was measured in venous blood. |
Tumor necrosis factor was measured in pre, after the maximum power phase of the rectangular test and after the recovery phase in pre and post intervention (8 weeks) in both groups. |
|
Secondary |
C-reactive protein (inflammatory marker) |
During the rectangular test, C-reactive protein (mg/L) was measured in venous blood. |
C-reactive protein was measured in pre, after the maximum power phase of the rectangular test and after the recovery phase in pre and post intervention (8 weeks) in both groups. |
|
Secondary |
Monocyte chemoattractant protein-1 (inflammatory marker) |
During the rectangular test, monocyte chemoattractant protein-1 (pg/ml) was measured in venous blood. |
Monocyte chemoattractant protein-1 was measured in pre, after the maximum power phase of the rectangular test and after the recovery phase in pre and post intervention (8 weeks) in both groups. |
|
Secondary |
Hemoglobin (oximetry marker) |
During the rectangular test, hemoglobin (g/dL) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain) |
Hemoglobin was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.) |
|
Secondary |
Hematocrit (oximetry marker) |
During the rectangular test, hematocrit (%) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain) |
Hematocrit was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.) |
|
Secondary |
Oxygen saturation (oximetry marker) |
During the rectangular test, oxygen saturation (%) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain) |
Oxygen saturation was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.) |
|
Secondary |
Oxygen partial pressure (oximetry marker) |
During the rectangular test, oxygen partial pressure (mmHg) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain) |
Oxygen partial pressure was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.) |
|
Secondary |
Carbon dioxide partial pressure (oximetry marker) |
During the rectangular test, carbon dioxide partial pressure (mmHg) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain) |
Carbon dioxide partial pressure was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.) |
|
Secondary |
Oxyhemoglobin (oximetry marker) |
During the rectangular test, oxyhemoglobin (%) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain) |
Oxyhemoglobin was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.) |
|
Secondary |
Carboxyhemoglobin (oximetry marker) |
During the rectangular test, carboxyhemoglobin (%) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain) |
Carboxyhemoglobin was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.) |
|
Secondary |
Deoxyhemoglobin (oximetry marker) |
During the rectangular test, deoxyhemoglobin (%) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain) |
Deoxyhemoglobin was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.) |
|
Secondary |
Methemoglobin (oximetry marker) |
During the rectangular test, methemoglobin (%) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain) |
Methemoglobin was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.) |
|
Secondary |
Total blood oxygen concentration (oximetry marker) |
During the rectangular test, total blood oxygen concentration (mmol/L) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain) |
Total blood oxygen concentration was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.) |
|
Secondary |
Total blood carbon dioxide concentration (oximetry marker) |
During the rectangular test, total blood carbon dioxide concentration (mmol/L) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain) |
Total blood carbon dioxide concentration was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.) |
|
Secondary |
Oxygen partial pressure at 50% oxygen saturation (oximetry marker) |
During the rectangular test, oxygen partial pressure at 50% oxygen saturation (mmHg) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain) |
Oxygen partial pressure at 50% oxygen saturation was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.) |
|
Secondary |
Relative physiological Shunt (oximetry marker) |
During the rectangular test, relative physiological Shunt (%) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain) |
Relative physiological Shunt was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.) |
|
Secondary |
Alveolar-arterial gradient (oximetry marker) |
During the rectangular test, alveolar-arterial gradient (mmHg) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain) |
Alveolar-arterial gradient was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.) |
|
Secondary |
Bicarbonate (metabolic marker) |
During the rectangular test, bicarbonate (mmol/L) wasa measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain) |
Bicarbonate was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.) |
|
Secondary |
Glucose (metabolic marker) |
During the rectangular test, glucose (mg/dL) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain) |
Glucose was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.) |
|
Secondary |
Lactate (metabolic marker) |
During the rectangular test, lactate (mmol/L) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain) |
Lactate was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.) |
|
Secondary |
pH (metabolic marker) |
During the rectangular test, pH was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain) |
pH was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.) |
|
Secondary |
Actual base excess (metabolic marker) |
During the rectangular test, actual base excess (mmol/L) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain) |
Actual base excess was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.) |
|
Secondary |
Standard base excess (metabolic marker) |
During the rectangular test, standard base excess (mmol/L) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain) |
Standard base excess was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.) |
|
Secondary |
Sodium (metabolic marker) |
During the rectangular test, sodium (mmol/L) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain) |
Sodium was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.) |
|
Secondary |
Potassium (metabolic marker) |
During the rectangular test, potassium (mmol/L) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain) |
Potassium was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.) |
|
Secondary |
Chloride (metabolic marker) |
During the rectangular test, chloride (mmol/L) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain) |
Chloride was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.) |
|
Secondary |
Calcium (metabolic marker) |
During the rectangular test, calcium (mmol/L) was measured using capillary blood obtained from a finger prick and analyzed in a blood gas analyzer (ABL90 FLEX PLUS, Radiometer Iberica, Spain) |
Calcium was analyzed pre, at the end of the FatMax phase, VT1, VT2, maximum power, FatMax2 and after the recovery phase of the rectangular test in pre and post intervention (8 weeks) in both groups.) |
|